ADVA
13.5.2020 09:02:19 CEST | Business Wire | Press release
ADVA (FSE: ADV) and 6WIND today announced that German telecommunication carrier WiTCOM is using ADVA’s Ensemble Connector and 6WIND’s Turbo IPsec vRouter as key components of its new edge cloud platform. The open multi-vendor solution enables WiTCOM to power its smart city initiative with network functions virtualization (NFV) and universal customer premises equipment (uCPE). Built on best-of-breed technology from five leading suppliers, the solution supports the rapid and efficient rollout of IoT, video and next-generation services across WiTCOM’s IPv6 network and enables easy scalability for global deployments. Other partners in the project are Advantech, dacoso and Dell Technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005054/en/
“We took an innovative approach for an open multi-vendor solution to power our smart city initiative working with 6WIND, ADVA, Advantech, Dell Technologies and dacoso,” said Volker Bodenbach, head of technology and operations, WiTCOM. “Together we designed a secure open platform that powers edge cloud for IoT, video and next-generation services across our IPv6 network that can further be deployed worldwide across many verticals.”
WiTCOM’s new multi-vendor platform is composed of technologies optimized for edge cloud architecture. The uCPE approach brings dramatically increased efficiency and scale to the ICT service provider’s business. It also ensures that its customers benefit from ultimate choice and flexibility. Now, WiTCOM can streamline multiple virtual network functions (VNFs) on a single installation deployed close to the end customer, helping cities to digitalize their infrastructure and take advantage of the latest innovation in areas such as traffic control, surveillance and IoT.
“Our Ensemble Connector is the ideal solution for hosting and managing demanding uCPE applications. It’s now giving WiTCOM the power of the cloud along with several other benefits, such as zero-touch provisioning and platform security. It also provides access to the Ensemble Harmony ecosystem, which includes a wide variety of onboarded commercial VNFs,” commented James Buchanan, general manager, Edge Cloud, ADVA. “With its new uCPE network, WiTCOM can respond in an instant to customer demands and empower municipal networks to test out offerings and ideas. It will help accelerate the fourth industrial revolution and be a key tool in transforming cities into safer, less wasteful and more pleasant places to live.”
“6WIND’s vRouters provide the high-performance virtual routing foundation required for secure, scalable uCPE solutions,” said Eric Carmès, founder and CEO, 6WIND. “We are proud to work with WiTCOM alongside our partners ADVA, Advantech, dacoso and Dell Technologies to create an industry-leading smart city initiative for IoT, video and additional services.”
“Our task was to combine the components for this managed edge cloud solution into a finely tuned overall solution,” explained Karsten Geise, head of business and development, dacoso. “IoT via IPv6 public networks will be of great interest to many companies in the future if it meets such high security and automation requirements.”
“WiTCOM’s smart city blueprint extends the cloud infrastructure to the IoT edge, building a solid and open foundation to run innovative mobility and security services,” said James Yang, VP, Cloud-IoT Group, Advantech. “Our white box uCPE solutions help service providers like WiTCOM enable this intelligent edge with optimized platforms that provide ample computing power and rich connectivity while meeting edge environmental and mechanical constraints.”
Further information is available in this case study: https://adva.li/witcom-case-study .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005054/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom